FDA Allows HalcyGen's IND Application – Pivotal US-Based Clinical Trials to Proceed

Published: Jun 17, 2008

MELBOURNE, Australia, June 17, 2008-HalcyGen Pharmaceuticals Limited (ASX:HGN) has received approval from the US Food and Drug Administration (FDA) to begin pivotal pharmacokinetic* (PK) studies in the United States. These studies are the precursor to SUBATM-Itraconazole product registration.

Back to news